Intercalated chemotherapy and erlotinib for non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations

Among attempts to delay development of resistance to tyrosine kinase inhibitors (TKIs) in patients with advanced non-small cell lung cancer (NSCLC) with activating mutations of epidermal growth factor receptor (EGFR), intercalated therapy has not been properly evaluated. In a phase II trial, 38 pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Zwitter, Matjaz, Rajer, Mirjana, Stanic, Karmen, Vrankar, Martina, Doma, Andrej, Cuderman, Anka, Grmek, Marko, Kern, Izidor, Kovac, Viljem
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5074447/
https://www.ncbi.nlm.nih.gov/pubmed/27261103
http://dx.doi.org/10.1080/15384047.2016.1195049

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5074447/
https://www.ncbi.nlm.nih.gov/pubmed/27261103
http://dx.doi.org/10.1080/15384047.2016.1195049

Ejemplares similares